Journal of Immunotherapy and Precision Oncology

What Journal of Immunotherapy and Precision Oncology does

Journal of Immunotherapy and Precision Oncology (JIPO) is a peer-reviewed scientific journal focused on publishing research at the intersection of immunotherapy and precision oncology. Founded in 2017 and headquartered in Cincinnati, Ohio, the journal serves clinicians, researchers, and academic audiences working in immuno-oncology, targeted therapeutics, and related translational science. The journal is hosted on the KGL Meridan publishing platform, which provides the underlying submission, peer-review, and dissemination infrastructure.

JIPO's core product is its publication output, which delivers original research, reviews, and case reports in its therapeutic niche. No additional product modules, technology stack, or proprietary platforms beyond the underlying journal hosting are documented in the source data. The operating team is small, with 7 reported employees, consistent with an independently produced specialty journal rather than a large commercial publisher.

The business model is not disclosed in the source material. Based on industry norms for specialty peer-reviewed journals, likely revenue mechanics include article processing charges (APCs), individual and institutional subscriptions, reprint fees, and possible advertising or sponsored supplements; however, no pricing details, customer segments, or distribution channels are present in the input. There is no documented funding history, ownership structure, parent entity, or management team in the available data.

Name

Journal of Immunotherapy and Precision Oncology

Website

https://jipoonline.org

Company type

Private

Headcount range

1–10 employees

Short description

Journal of Immunotherapy and Precision Oncology (JIPO) is a peer-reviewed scientific journal founded in 2017 in Cincinnati, Ohio, publishing original research in immunotherapy and precision oncology for clinicians and academic researchers.

Ownership category

akta.pro rank

GTM type

B2B

Offering type

Digital Commerce or Content

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Core offering

Journal of Immunotherapy and Precision Oncology (JIPO) is a peer-reviewed scientific journal that publishes original research, reviews, and clinical content focused on immunotherapy and precision oncology. The journal is hosted and distributed online through the KGL Meridan publishing platform and operates as a single scholarly publication product.

Product overview

The Journal of Immunotherapy and Precision Oncology (JIPO) is a scientific publication that appears to operate as a single journal product hosted on the KGL Meridan platform. The source data provides minimal detail about the journal's structure or any additional modules/features beyond its core publication offering.

Differentiator

Problem solved

Functional benefit

Products and services

• Journal of Immunotherapy and Precision Oncology (JIPO) A peer-reviewed scientific journal publishing research, reviews, and clinical content on immunotherapy and precision oncology, intended for medical researchers, clinicians, oncologists, immunologists, and academic medical institutions. The journal is hosted online through the KGL Meridan publishing platform.

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Broad incumbents

• JAMA Oncology: Leading general oncology journal publishing research across all cancer topics including immunotherapy and precision oncology, serving the same clinical and research audience as JIPO.
• The Lancet Oncology: Premier oncology journal covering clinical and translational cancer research including immunotherapy and precision oncology, with significantly higher impact and reach than JIPO.
• Nature Reviews Cancer: High-impact review journal covering all areas of oncology research, including immunotherapy and precision oncology, with significantly broader scope and prestige than JIPO.
• Clinical Cancer Research: Established AACR journal covering innovations in clinical and translational cancer research, including immunotherapy and precision oncology, with broader scope but overlapping topic coverage with JIPO.

Direct peers

• Journal for ImmunoTherapy of Cancer (JITC): Peer-reviewed open-access journal specifically focused on immuno-oncology research, directly overlapping JIPO's immunotherapy scope and serving the same author and reader community.
• Precision Oncology (Springer Nature): Journal specifically focused on precision medicine approaches in oncology, directly aligned with JIPO's precision oncology scope and intended audience.
• OncoImmunology: Peer-reviewed journal covering the intersection of oncology and immunology, directly comparable to JIPO's scope and target readership.
• Cancer Immunology Research: AACR-published journal dedicated to immunology and immunotherapy in cancer, covering the same research topics as JIPO with an overlapping audience of researchers and clinicians.

Emerging players

• Frontiers in Oncology: Open-access journal covering all areas of oncology research including immunotherapy and precision oncology, with a similar open-access model and broad topic coverage.
• Journal of Translational Medicine: Open-access journal publishing translational research including immunotherapy and precision medicine approaches, with overlapping readership and similar open-access positioning.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/jipoeditors

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Journal of Immunotherapy and Precision Oncology